Electroporation

INOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020

Monday, July 27, 2020 - 1:00pm

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the availability and timing of data from the company's ongoing Phase 1 clinical trial of INO-4800 and the company's plans and ability to outsource manufacturing of its delivery devices to contract manufacturers.

Key Points: 
  • This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the availability and timing of data from the company's ongoing Phase 1 clinical trial of INO-4800 and the company's plans and ability to outsource manufacturing of its delivery devices to contract manufacturers.
  • Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, our ability to secure adequate third-party manufacturing resources for the production of our product candidates, including the transfer of necessary processes, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and other filings we make from time to time with the Securities and Exchange Commission.
  • There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate.
  • Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

COVID-19 Impact & Recovery Analysis- Global Electroporation Instruments Market 2020-2024 | Growing Demand for Monoclonal Antibodies to Boost Growth | Technavio

Thursday, July 23, 2020 - 3:00am

Technavio has been monitoring the global electroporation instruments market size and it is poised to grow by USD 72.67 million during 2020-2024.

Key Points: 
  • Technavio has been monitoring the global electroporation instruments market size and it is poised to grow by USD 72.67 million during 2020-2024.
  • View the full release here: https://www.businesswire.com/news/home/20200722005728/en/
    Technavio has announced its latest market research report titled Global Electroporation Instruments Market 2020-2024 (Graphic: Business Wire)
    Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19.
  • Please request Latest Free Sample Report on Covid-19 Impact
    What was the value of the electroporation instruments market in 2019?
  • The rising demand for monoclonal antibodies has been instrumental in driving the growth of the market.

Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics

Wednesday, July 15, 2020 - 7:00am

OXFORD, England, July 15, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • OXFORD, England, July 15, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO).
  • This newly issued patent adds to the expanding foundational patent estate held by Evox and further reinforces the Company's leading position within the field of exosome-mediated RNA drug delivery.
  • The recently issued US patent (U.S. Patent 10,704,047) provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.
  • Dr Per Lundin, Chief Operating Officer of Evox, commented: "We are very pleased to have been granted another foundational patent, reflecting our scientific and IP leadership in the exosome therapeutics space.

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

Wednesday, July 8, 2020 - 7:00am

APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors.

Key Points: 
  • APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors.
  • In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.
  • "Securing access to MaxCyte's ExPERT platform and unique electroporation technology is a crucial next step in the clinical advancement of our lead checkpoint inhibition Cbl-b candidate APN401," said Peter Llewellyn-Davies, CEO of APEIRON Biologics.
  • APEIRON's APN401 clinical program is a "first-in-class" autologous cell therapy for strengthening immunoreactivity via the intra-cellular master checkpoint Cbl-b.

DGAP-News: APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

Wednesday, July 8, 2020 - 6:07pm

APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors.

Key Points: 
  • APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors.
  • In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.
  • "Securing access to MaxCyte's ExPERT platform and unique electroporation technology is a crucial next step in the clinical advancement of our lead checkpoint inhibition Cbl-b candidate APN401," said Peter Llewellyn-Davies, CEO of APEIRON Biologics.
  • APEIRON's APN401 clinical program is a "first-in-class" autologous cell therapy for strengthening immunoreactivity via the intra-cellular master checkpoint Cbl-b.

Electroporation Instruments Market 2020-2024 | Demand for Monoclonal Antibodies to Boost Growth | Technavio

Wednesday, July 1, 2020 - 1:51pm

Our electroporation instruments market report covers the following areas:

Key Points: 
  • Our electroporation instruments market report covers the following areas:
    This study identifies high demand for biopharmaceuticals as one of the prime reasons driving the electroporation instruments market growth during the next few years.
  • We provide a detailed analysis of vendors operating in the electroporation instruments market, including some of the vendors such as BEX Co. Ltd., Bio-Rad Laboratories Inc., Celetrix LLC, Cellectricon AB, Eppendorf AG, Harvard Bioscience Inc., Lonza Group Ltd., MaxCyte Inc., Merck KGaA, and Thermo Fisher Scientific Inc.
  • Backed with competitive intelligence and benchmarking, our research reports on the electroporation instruments market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Global Market Outlook for the Non-Viral Transfection Reagents and Systems Market 2020-2030 - ResearchAndMarkets.com

Monday, June 22, 2020 - 10:46am

The "Non-Viral Transfection Reagents and Systems Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Viral Transfection Reagents and Systems Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022.
  • In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing.
  • A detailed assessment of the competitive landscape of various types of non-viral transfection systems, including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system.

Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001

Tuesday, June 16, 2020 - 1:00pm

ITI will leverage Ichors TriGrid Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.

Key Points: 
  • ITI will leverage Ichors TriGrid Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.
  • DNA vaccines delivered by conventional injection have experienced challenges to delivery efficiency, resulting in suboptimal immune responses in clinical trials.
  • We are pleased to collaborate with a recognized leader in the delivery of nucleic acid-based medicines and we look forward to initiating patient dosing in 2021.
  • Ichor Medical Systems clinical stage TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated nucleic acid administration in humans.

OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System

Wednesday, May 27, 2020 - 2:00pm

The European Patent Office intends to grant a patent covering OncoSec's gene therapy and electroporation for the treatment of malignancies.

Key Points: 
  • The European Patent Office intends to grant a patent covering OncoSec's gene therapy and electroporation for the treatment of malignancies.
  • Additionally, the European Patent Office also intends to grant a second patent protecting OncoSec's next-generation electroporation gene delivery system focused on the treatment of internal or visceral lesions.
  • The Canadian Intellectual Property Office intends to grant a patent protecting OncoSec's electroporation method for treating microscopic tumors.
  • "OncoSec continues to prioritize the expansion of its intellectual property portfolio across multiple facets of its technology," said Keir Loiacono, Vice President, Corporate Development at OncoSec Medical Incorporated.

Research Report with COVID-19 Forecasts- Electroporation Instruments Market 2020-2024 | Demand for Monoclonal Antibodies to Boost Growth | Technavio

Saturday, May 23, 2020 - 4:00am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40621

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40621
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our electroporation instruments market report covers the following areas:
    This study identifies high demand for biopharmaceuticals as one of the prime reasons driving the electroporation instruments market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the electroporation instruments market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.